Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Screening and brief interventions for alcohol misuse delivered in the community pharmacy setting
ISRCTN ISRCTN40380499
ClinicalTrials.gov identifier
Public title Screening and brief interventions for alcohol misuse delivered in the community pharmacy setting
Scientific title Screening and brief interventions for alcohol misuse delivered in the community pharmacy setting: a pilot study using a pragmatic cluster randomised controlled trial design
Acronym N/A
Serial number at source N/A
Study hypothesis Excessive alcohol consumption causes substantial morbidity and mortality. Screening, followed by brief interventions, is effective in reducing alcohol consumption and can be delivered in primary care. Evidence from small, proof-of-concept studies, shows that screening for excessive alcohol consumption can be delivered in community pharmacies, and can be followed by the delivery of brief interventions to clients identified as harmful or hazardous drinkers. A large-scale randomised controlled trial (RCT) of screening and brief interventions in the community pharmacy setting is needed to derive evidence of the effectiveness and cost-effectiveness of this approach. Firstly, a pilot study is needed to assess recruitment, participation and follow-up rates, to derive accurate data (including loss to follow up rates and effect size estimates) to inform sample size calculations for the RCT. In addition, the acceptability of this novel service to service providers and users needs to be explored.
Lay summary
Ethics approval Grampian Local Ethics Committee and NHS R&D approved on the 14th January 2010 (ref: 09/S0802/119)
Study design Pragmatic cluster randomised controlled pilot study
Countries of recruitment United Kingdom
Disease/condition/study domain Alcohol misuse
Participants - inclusion criteria 1. Community pharmacists and staff from 20 community pharmacies (i.e. 10 pharmacies in each group)
2. Adult clients presenting in participating community pharmacies
3. Clients aged 18 or over, either sex
Participants - exclusion criteria 1. Clients who have already been screened
2. Received an alcohol brief intervention elsewhere
3. Clients identified as dependent drinkers
Anticipated start date 05/02/2010
Anticipated end date 05/02/2011
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 100 clients to be screened within a two-month period (in 20 pharmacies)
Interventions Each pharmacy will be required to screen 100 clients within a two-month period. Based on the proof-of-concept studies, 40% are expected to be identified as harmful or hazardous drinkers.

All adult clients entering the community pharmacy will be eligible for screening (in control and intervention pharmacies). A tally sheet will be used in each participating pharmacy to record clients who refuse to undertake screening or brief interventions. Any trained member of the pharmacy team will invite the client to complete the Fast Alcohol Screening Test (FAST). Clients who score above the threshold score (greater than 3) will be invited to have a consultation with the pharmacist to discuss participation in the study. Clients who do not consent will be given the standard information leaflet about healthy lifestyle mentioned above and thanked for participating in the screening activity. Clients who score below the threshold score will also be given this leaflet.

All clients who are eligible (i.e. FAST score greater than 3) and who consent to participate, will be asked to provide written consent and then asked to complete the baseline questionnaire. The purpose of this questionnaire will be to collect additional information on alcohol consumption and demographic information (including their full postal address for the dissemination of follow-up surveys). They will also be informed that a short questionnaire will be sent to them at three and six months to explore their alcohol consumption.

Clients in the control group pharmacies will then be given a generic information leaflet about healthy lifestyle and thanked for their involvement. Clients in the intervention group pharmacies will receive a brief intervention to raise their awareness of their alcohol consumption in relation to recommended limits. The Reference Group (see later) will devise referral criteria that the pharmacists in both groups can use if they suspect a client requires referral to specialist services.
Primary outcome measure(s) 1. Average screening rate per pharmacy per week
2. Average recruitment rate per pharmacy per week
3. Number or proportion of clients who score greater than 3 using FAST
4. Self-reported measures of alcohol consumption (which may include number of episodes of 'binge' drinking, alcohol free days)
5. Follow-up rate at three and six months
6. Number of referrals to other agencies
7. Identification of barriers and facilitators to delivering screening and brief interventions in the community pharmacy setting (pharmacy staff and client perspective)
8. Exploration of the public's opinion of screening and brief interventions in the community pharmacy setting

Data to derive outcome measures (e.g. FAST score, other measures of alcohol consumption) will be collected at baseline, three and six months. Baseline data will be collected by pharmacy staff during the screening process and pharmacist consultation. Data at three and six months will be collected from clients using mailed questionnaires. The pharmacists and staff will be required to document additional information including the duration of screening and brief intervention consultations.
Secondary outcome measure(s) No secondary outcome measures
Sources of funding Chief Scientist Office of the Scottish Executive Health Department (UK)
Trial website
Publications
Contact name Dr  Margaret  Watson
  Address Centre of Academic Primary Care
University of Aberdeen
Westburn Road
  City/town Aberdeen
  Zip/Postcode AB25 2AY
  Country United Kingdom
  Tel +44 (0)1224 553785
  Fax +44 (0)1224 550683
  Email m.c.watson@abdn.ac.uk
Sponsor University of Aberdeen (UK)
  Address c/o Dr Liz Rattray, Deputy Director
Research & Innovation
King's College
  City/town Aberdeen
  Zip/Postcode AB24 3FX
  Country United Kingdom
  Tel +44 (0)1224 274 369
  Fax +44 (0)1224 272 319
  Email e.rattray@abdn.ac.uk
  Sponsor website: http://www.abdn.ac.uk/AURIS_Research/
Date applied 05/02/2010
Last edited 16/03/2010
Date ISRCTN assigned 16/03/2010
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central